Australia's most trusted
source of pharma news
Thursday, 09 October 2025
Posted 9 October 2025 AM
AstraZeneca's next move in oncology has been revealed with an MSAC submission naming lung cancer treatment Orpathys and confirming the company is looking to secure PBS reimbursement.
In 2011, AstraZeneca entered into a global licensing, co-development, and commercialisation agreement with Hong Kong-based HUTCHMED with Orpathys securing conditional approval in China in 2021.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.